Skip to main content
Home > BC Innovations > Targets & Mechanisms

Chronological Index of : Targets & Mechanisms

 Current Issue
  • High five for Arsanis

    Arsanis finds neutralizing antibody against five Staphylococcus aureus toxins

    Arsanis used Adimab's technology to find an antibody that hits five bacterial toxins from one pathogen, and the bet is that the approach can fish out other hot-spot epitopes.

    Published on 2/12/2015
  • Figure: A hole in five toxins

    High five for Arsanis Targets & Mechanisms A hole in five toxins Finding antibodies that cross-react with multiple toxins from Staphylococcus aureus is a long shot given the low 25-27% homology between the organism…

    Published on 2/12/2015
  • Going TIGITal

    Genentech is combining antibodies against TIGIT and PD-L1 for cancer immunotherapy

    Genentech's discovery that TIGIT acts as a fine tuner for PD-1 via a new mechanism creates possibilities for combination therapies, but the company isn't revealing its plans.

    Published on 1/29/2015
  • Figure: TIGITal signaling

    Going TIGITal Targets & Mechanisms TIGITal signaling The CD226 and TIGIT co-signaling receptor pathway on T cells. I. On activated T cells, CD226 forms homodimers to interact with its ligand, PVR, on antigen-…

    Published on 1/29/2015
  • Personalized tumor vaccines

    Personalized tumor vaccines derived from tumor-specific mutant epitopes

    Mutant antigens in tumor cells targeted by anti-PD-1 therapies can be used to generate tumor-specific vaccines, and might mark the start of personalized combos in immunotherapy.

    Published on 1/29/2015
  • Targets & Mechanisms: Unearthing antibiotics

    New antimicrobial peptides from soil bacteria

    Two new techniques for exploiting soil bacteria to find antibiotics have uncovered compound classes and targets that could impact the field even more than the pair of antimicrobials discovered.

    Published on 1/22/2015
  • Pseudo-allergy exposed

    One receptor could help screen out allergy-inducing compounds during discovery

    A single receptor found to mediate allergic drug reactions could lead to an antidote and allow compounds to be screened out early during drug discovery.

    Published on 1/22/2015
  • Figure: The THIQ IQ

    Pseudo-allergy exposed Targets & Mechanisms The THIQ IQ Structures of the classic basic secretagogue 48/80, its cyclized monomer and representative members of neuromuscular blocking or anti-microbial drugs that …

    Published on 1/22/2015
  • Box: Dirt Silk Road

    Unearthing antibiotics Targets & Mechanisms Dirt silk road Historically, soil-based bacteria were routinely mined for antibiotics, but the practice has lost ground to synthetic approaches involving structure-based …

    Published on 1/22/2015
  • Resurrecting a magic bullet

    Heidelberg Pharma has resuscitated a long-dead ADC toxin with updated conjugation techniques, and its partner Roche has thrown the company a lifeline that could help validate the platform.

    Published on 12/18/2014
  • Lysin in wait

    Micreos and ContraFect are separately developing phage lysins, which are not prone to bacterial resistance, as complements to antibiotics.

    Published on 12/11/2014
  • PIEZO de resistance

    A Duke team has found a new role for PIEZO calcium channels in cartilage damage, suggesting channel inhibitors could be developed for joint injury or osteoarthritis.

    Published on 12/11/2014
  • Terazosin reborn

    Chinese researchers have found that the generic alpha-blocker terazosin prevents apoptosis and want to pursue it for stroke, but they will need to navigate a landscape of difficult preclinical models.

    Published on 12/11/2014
  • Greasing insulin

    The once discarded target GPR120 has led to the discovery of an entirely new class of fatty acids that could restore insulin sensitivity in patients with diabetes.

    Published on 11/6/2014
  • Branching out in pancreatic cancer

    Changes in circulating levels of branched-chain amino acids detectable 2-5 years before the onset of pancreatic cancer could lead to diagnostic markers for the indication.

    Published on 10/23/2014
  • Alnylam interrupts preeclampsia

    Alnylam has generated an siRNA conjugate that blocks angiotensin-induced hypertension without causing fetal toxicity in a rat model of preeclampsia.

    Published on 10/16/2014
  • BetaLogics' in vitro beta cells

    BetaLogics and University of British Columbia researchers have developed an in vitro protocol to generate mature insulin-producing beta-like cells from human pluripotent stem cells - a major milestone in the development…

    Published on 10/9/2014
  • MIDAS touch vaccine

    A vaccine against the fibrinogen-binding MIDAS domain in the ebpA protein of Enterococcus faecalis could provide a solution to the widespread problem of catheter-associated urinary tract infections.

    Published on 10/9/2014
  • Ral-lying around Ras

    A University of Colorado-led team has demonstrated anticancer efficacy for new small molecule inhibitors of Ral proteins - a family of Ras-like GTPases often overlooked in favor of their Ras cousins.

    Published on 10/9/2014
  • ALK7's obese functions

    Researchers have shown that inhibiting ALK7 can increase energy expenditure in fat cells and suggest the protein could be a target for obesity. Acceleron Pharma has licensed the findings and is pursuing a discovery …

    Published on 9/25/2014
  • A chromatin target for ALL

    An NYU School of Medicine-GSK collaboration has shown that an inhibitor of the chromatin regulator JMJD3 could help treat T cell acute lymphoblastic leukemia and might avoid the safety pitfalls of other notch 1-targeted…

    Published on 9/11/2014
  • Destabilizing data in CF

    In vitro data from two academic labs show combinations of Kalydeco ivacaftor and lumacaftor destabilize the CFTR channel. Although the new findings are at odds with Vertex's positive clinical results, they are prompting…

    Published on 9/4/2014
  • A cultured approach to ALS therapy

    The mechanisms by which dysfunctional glial cells contribute to ALS have remained poorly defined. Now, Harvard University researchers have identified a therapeutic target-prostaglandin D2 receptor subtype DP1-and shown …

    Published on 8/28/2014
  • PAX6 drives differentiation of skin epithelial stem cells to limbal stem cells

    Targets & Mechanisms: Corneal perspectives Figure 1. PAX6 drives differentiation of skin epithelial stem cells to limbal stem cells. Two new approaches that promote regenerative therapies for corneal transplants have…

    Published on 8/21/2014
  • Corneal perspectives

    Two independent findings could increase the availability of tissue for corneal transplants. A UCSD team has identified key factors needed to culture the limbal stem cells necessary for clear vision. A Harvard team has …

    Published on 8/21/2014

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993